Shop Talk

AACR Research Inaugurates New Leadership The American Association for Cancer Research (AACR) welcomes Antoni Ribas, MD, PhD, FAACR, as President of the organization for 2020-2021. He is Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles (UCLA), Director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program, and Director of the Parker Institute for Cancer Immunotherapy Center at UCLA. He is an internationally recognized physician-scientist whose translational and clinical research focuses on developing new therapeutic options for patients with malignant melanoma.FigureAntoni Ribas, MD, PhD, FAACR: Antoni Ribas, MD, PhD, FAACR“As I enter my term as AACR President in these unprecedented times, I look forward to helping the organization successfully move forward in response to challenges associated with the COVID-19 pandemic,” said Ribas. “I am also honored to be following in the footsteps of the past AACR Presidents, and I appreciate the opportunity to work with Dr. Foti, the AACR officers, and with the AACR's membership and staff. In the next 12 months, we will continue to shape the future of cancer research and help bring more lifesaving breakthroughs to patients with cancer around the world.” Ribas, an AACR member since 1999, is currently serving as chair for the AACR Annual Meeting 2020 Program Committee, and as a scientific editor of the AACR journal Cancer Discovery. He was elected to the 2020 class of Fellows of the AACR Academy, and also received the AACR-CRI Lloyd J. Old Award in Cancer Immunology in 2018 and the AACR Richard and Hinda Rosenthal Memorial Award in 2016. Ribas earned his doctorate from the Autonomous University of Barcelona, Spain, and his medical degree from the University of Barcelona. After serving as an intern and resident at the University Hospital Vall d'Hebron in Barcelona, he moved to UCLA, joining the faculty in 2001. Additional AACR Leadership Changes David A. Tuveson, MD, PhD, FAACR, Director of the Cold Spring Harbor Laboratory Cancer Center in New York, was inducted as the AACR President-Elect. Elaine R. Mardis, PhD, FAACR, who holds the Nationwide Foundation Endowed Chair in Genomic Medicine and is Co-Executive Director of the Institute for Genomic Medicine at Nationwide Children's Hospital in Columbus, Ohio, now serves as Past President. David A. Tuveson, MD, PhD, FAACR: David A. Tuveson, MD, PhD, FAACRElaine R. Mardis, PhD, FAACR: Elaine R. Mardis, PhD, FAACRIn addition, the following distinguished cancer researchers have been elected and/or appointed to the AACR Board of Directors for the 2020-2023 term: Silvia Chiara Formenti, MD, Professor and Chair of Radiation Oncology, Department of Radiation Oncology; Sandra and Edward Meyer Professor of Cancer Research and Associate Director, Meyer Cancer Center, Weill Cornell Medical College; Radiation Oncologist-in-Chief and Attending Physician, NewYork-Presbyterian Hospital. Elaine Fuchs, PhD, FAACR, Rebecca C. Lancefield Professor, Laboratory of Mammalian Cell Biology & Development, The Rockefeller University, New York; and investigator, Howard Hughes Medical Institute. Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology); Professor of Pharmacology; Chief of Medical Oncology; Associate Cancer Center Director for Translational Research; Director, Thoracic Oncology Research Program; and Interim Director, Yale Center for Immuno-Oncology, Yale Cancer Center, New Haven, Conn. Ira Mellman, PhD, Vice President of Cancer Immunology, Genentech, South San Francisco, California; Professor of Biochemistry and Biophysics, University of California San Francisco; senior fellow, Lincoln College, University of Oxford, UK. Suzanne L. Topalian, MD, Bloomberg-Kimmel Professor of Cancer Immunotherapy; Professor of Surgery and Oncology, Johns Hopkins University School of Medicine; Director, Melanoma Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore. Also, Scott A. Armstrong, MD, PhD, was appointed to the AACR Board of Directors to fill President-Elect Tuveson's position as Director. Armstrong will hold the position for the final year of Tuveson's 3-year term. Armstrong is Chair of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute and David G. Nathan Professor of Pediatrics at Harvard Medical School in Boston. Silvia Chiara Formenti, MD: Silvia Chiara Formenti, MDElaine Fuchs, PhD, FAACR: Elaine Fuchs, PhD, FAACRRoy S. Herbst, MD, PhD: Roy S. Herbst, MD, PhDIra Mellman, PhD: Ira Mellman, PhDSuzanne L. Topalian, MD: Suzanne L. Topalian, MDScott A. Armstrong, MD, PhD: Scott A. Armstrong, MD, PhDThe Cancer Genome Atlas Honored With 2020 Team Science Awards The AACR has recognized the founding members and the current project team associated with The Cancer Genome Atlas (TCGA) with 2020 AACR Team Science Awards. This is the first time the AACR has honored TCGA with an award, and the AACR is proud to recognize the early pioneers who conceptualized and implemented the initial pilot project. The AACR is honoring the seminal contributions of Anna D. Barker, PhD, and Francis S. Collins, MD, PhD, who were directly responsible for the project's inception and establishment.Anna D. Barker, PhD: Anna D. Barker, PhDFrancis S. Collins, MD, PhD: Francis S. Collins, MD, PhDThe Cancer Genome Atlas Project began in 2006 as a joint effort between the National Cancer Institute and the National Human Genome Research Institute, bringing together researchers from diverse disciplines and multiple institutions to create a detailed catalog of genomic changes associated with specific types of cancer. TCGA has since opened new avenues of research to improve the prevention, diagnosis, and treatment of numerous cancers. The TCGA founders and current project team members are being recognized for their extensive collaborations and ongoing efforts to generate one of the largest-ever sets of tumor characterization data. The AACR Team Science Award was established by the AACR and Eli Lilly and Co. in 2007 to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. The award recognizes an outstanding interdisciplinary team of researchers for their innovative and meritorious science that has advanced or may advance our fundamental knowledge of cancer, or a team that has applied existing knowledge to advancing the detection, diagnosis, prevention, or treatment of cancer. “This remarkable project has uniquely convened researchers from various scientific areas working in a number of institutions across the United States and Canada, and it continues to effectively serve as the premier model for team science initiatives,” said Margaret Foti, PhD, MD (hc), Chief Executive Officer of the AACR. “Importantly, the collective and publicly available genomic, proteomic, transcriptomic, and epigenomic data generated by the TCGA network have resulted in innumerable scientific publications and cancer research breakthroughs, which cumulatively have significantly increased our understanding of cancer. These new insights have impacted every area of cancer research and have increased our ability to prevent, diagnose, and treat cancer.” Since its inception, TCGA has resulted in the molecular characterization of more than 20,000 primary cancer and matched normal samples spanning 33 cancer types including cutaneous melanoma, endometrial cancer, glioblastoma, hepatocellular carcinoma, mesothelioma, prostate cancer, and thyroid cancer. The data generated by TCGA have highlighted chromosomal rearrangements, copy number alterations, DNA methylation events, and RNA expression changes that possess the ability to drive cancer initiation and progression. This comprehensive genetic knowledge has transformed our understanding of cancer. TCGA has enabled and driven the development of new technologies that have exponentially improved genetic sequencing capabilities and is the foremost initiative responsible for supporting the emergence and implementation of precision cancer medicine. In addition to these groundbreaking discoveries, TCGA has revolutionized cancer genomics research by establishing new standards and procedures for managing interdisciplinary teams of biological scientists, clinicians, computational scientists, and pathologists. TCGA has also been influential in developing and implementing universal policies that have made genomic data broadly available for public access. “Although we faced numerous challenges in the early planning, development, and management of a project of this scale, the founding team understood that TCGA promised to change the world for cancer research and cancer patients, which inspired us all to go to work and make it happen,” said Barker, Chief Strategy Officer at the Ellison Institute for Transformative Medicine, University of Southern California, and former Principal Deputy Director of the NCI. “Today, results from TCGA stand as a critical foundation for cancer research and a source of hope for patients.” “It's rewarding and humbling to be recognized with so many accomplished scientists who helped to conceive, launch, and establish TCGA,” said Collins, Director of the National Institutes of Health. “There was a tremendous amount of work across multiple disciplines to fully sequence cancer genomes, and the significance of discoveries to come out of TCGA cannot be overstated. TCGA continues to be one of the most important tools in the fight against cancer.” Also recognized with this award are past NCI Directors Andrew C. von Eschenbach, MD, and John E. Niederhuber, MD, whose leadership throughout the years of the TCGA pilot project were vital to the financial stability of the project and its continued success. Eric S. Lander, PhD, and Leland H. Hartwell, PhD, are recognized for their efforts associated with the establishment of the initial TCGA pilot project, specifically their contributions as Co-Chairs of the National Cancer Advisory Board's Working Group on Biomedical Technology. Because of their visionary oversight, this working group served as a ripe forum for early impactful discussions concerning the original TCGA concept that would ultimately result in the project's genesis. Collectively, these individuals are recognized for their extraordinary leadership and contributions to the formation of TCGA.Andrew C. von Eschenbach, MD: Andrew C. von Eschenbach, MDJohn E. Niederhuber, MD: John E. Niederhuber, MDEric S. Lander, PhD: Eric S. Lander, PhDLeland H. Hartwell, PhD: Leland H. Hartwell, PhDAlso being recognized with this prestigious award are 34 other individuals who contributed to the success of TCGA, including those who were, and some of whom continue to be, involved with various facets of the TCGA network. The second 2020 AACR Team Science Award is being presented to Jean Claude Zenklusen, PhD, and the 129 additional members of the current TCGA project team for their recent and ongoing efforts to functionalize the data generated by the project. Zenklusen has served as Director of TCGA in the NCI Center for Cancer Genomics since August 2013 and continues to lead the evolution of the program and all team members to further build upon the initial success of the TCGA pilot project.Jean Claude Zenklusen, PhD: Jean Claude Zenklusen, PhDResearchers Awarded Grant to Develop Safer Treatment for Inherited Blood Disorders With a new 4-year $3.5 million grant, researchers at Fred Hutchinson Cancer Research Center are working toward a safer form of a longstanding treatment for these patients. Today, the only cure for sickle cell disease is a bone marrow transplant. During these procedures, patients first undergo chemotherapy and/or radiation to destroy their diseased bone marrow. Healthy, blood-forming stem cells are then given directly into the patient's bloodstream. Scientists are now exploring whether gene editing can also fix those underlying defects. But this approach still requires strong doses of chemotherapy or radiation to help clear the way for the engineered cells to engraft, or take root. In both cases, these so-called “conditioning” regimens can cause severe toxicities. Their nonspecific nature can wreak havoc on healthy organs and tissues. With its new grant from the National Institutes of Health, the Fred Hutch team aims to minimize those toxicities. Hans-Peter Kiem, MD, PhD, and Roland Walter, MD, PhD, MS, will explore ways to precisely deliver powerful radioactive particles to blood and marrow cells while sparing other nonblood cells and tissues.Hans-Peter Kiem, MD, PhD: Hans-Peter Kiem, MD, PhDRoland Walter, MD, PhD, MS: Roland Walter, MD, PhD, MS“For the fields of transplantation and gene therapy, these conditioning regimens are a fundamental issue,” said Kiem, who holds the Stephanus Family Endowed Chair for Cell and Gene Therapy at Fred Hutch. “It's critical that we get these cells to engraft with the least amount of toxicity.” To do that, they want to trade the traditional, nontargeted preparative treatments for something far more precise. Their research will involve a particular radioactive particle called astatine-211, which is known as an “alpha emitter” because of the type of radiation it produces. “Alpha emitters are ideal for the precise delivery of potent amounts of radiation,” Walter said. That's because they can deliver a high dose of energy over a short distance; the damage is deposited locally to the targeted cells while minimizing damage to surrounding, nontargeted cells. Walter plans on fashioning a delivery vehicle for astatine-211 out of antibodies. These specialized immune proteins can home in on a specific surface marker on blood stem cells. He will engineer several antibodies and test the candidates in mice. Kiem then will take the most promising of these into the final steps of testing needed before they can be used in human patients. Kiem noted that other Fred Hutch scientists, like Brenda Sandmaier, MD, are testing a similar approach with alpha emitters for cancer patients in clinical trials. “We have spent decades improving conditioning regimens for transplant patients, and we're now on the leading edge of doing the same for gene therapy and genome editing,” he said. “The ultimate goal is to make these gene therapies safer and translate this work into patients.” Roswell Park Leukemia Chief Named Medical Director of Infusion Services Infusions of chemotherapy or other medications: They're facets of oncology that often make up a big portion of a patient's cancer care. It's treatment that can take up many hours in a clinic or in an inpatient setting, delivered by dedicated oncology nurses and physicians. At Roswell Park Comprehensive Cancer Center, that dedication is seen day in and day out by veteran staff member Eunice Wang, MD, who has been selected to lead this team as the newly appointed Medical Director of Infusion Services.Eunice Wang, MD: Eunice Wang, MDAt Roswell Park's Chemotherapy and Infusion Centers, patients get treatment regimens delivered directly into to their bloodstream. As Medical Director, Wang will oversee infusion services on the main campus and at Roswell Park's satellite clinics, focused on a patient-centric approach to care and treatment plans. Wang has served in multiple roles since joining Roswell Park in 2003, including Co-Chair of the Leukemia Translational Research Group and Physician Leader with the Chemotherapy and Infusion Center. She will continue in her role as Chief of Leukemia. Most recently, Wang has proved pivotal in disseminating vital information about patient care and safety at Roswell Park during the COVID-19 pandemic, having appeared on a live chat for patients, a webinar for physicians and a 30-minute television special. “Dr. Wang is a fierce and attentive patient advocate, which makes her the ideal person to lead Infusion Services,” noted Candace S. Johnson, PhD, President & CEO and M&T Bank Presidential Chair in Leadership at Roswell Park. “Her passion for outstanding care will be a guiding force for this important clinical program.” Wang earned her medical degree from the Keck School of Medicine, University of Southern California, and completed residency training in internal medicine at Yale-New Haven Hospital, Yale University. She completed a clinical hematology-oncology and research fellowship at Memorial Sloan Kettering Cancer Center. Her research focuses on the development of early-stage clinical trials for acute leukemias (AML, ALL) and myeloproliferative disorders. Melanoma Research Foundation Honors Dr. Andrew With Award The Sidney Kimmel Cancer Andrew E. PhD, who is being recognized with the Melanoma Research Foundation is the Professor in Cancer Associate Director for and Program Leader for Cancer Cell Biology & at E. PhD: Andrew E. PhDThe Award is presented to a in the who is to patient or scientific “I am honored that the Melanoma Research Foundation is our research team with a Award at their are to that were during COVID-19 and this grant from the Melanoma Research Foundation will make that said. research focuses on understanding the that cause cell and in of and therapeutic He has of their to malignant in The is currently of to In clinical researchers have patients being with to the often research will help new clinical trials therapies to help research also to or In and a team of researchers were a Team Science Award to He a team of researchers from the School of Medicine at in New York, and the Comprehensive Cancer Center at the University of in to are working to new therapeutic to treat the New Director of Cancer Institute at Named David MD, has been appointed Director of the Cancer Institute at which has an ongoing to to comprehensive cancer care in the the has services and at MD, David MD, the Cancer Institute at care the primary cancer together a team of recognized cancer advanced treatments and a of all dedicated to cancer services to patients and their to “We are Dr. will be leading the Cancer Institute at said Richard MD, and Director of the Cancer Institute and Vice President of Cancer Services at Health. is a and who also has strong Cancer throughout the look forward to with Dr. as he new cancer in the The Cancer Institute at currently a comprehensive of cancer services to cancer services medical radiation cancer cancer infusion cancer and a of and services are with Hospital, inpatient services and are as a in and and for his advanced in has a in and other procedures including advanced procedures for the treatment of and including cancer. He is a of at the and School of Medicine at “The goal of the Cancer Institute at is to a of to cancer care and to be a in cancer services in said a resident of Lloyd year is a tremendous to cancer care to It's for patients to get care in their than to or The COVID-19 our to the area for cancer plans a comprehensive cancer at Hospital patients a approach to cancer care in all oncology will be the campus of the Cancer Institute at it for patients and their care teams to and treatment plans. With a to the National Cancer Cold Spring Harbor patients will from leading cancer to joining Hospital, was Chief of and Surgery at of Medical Center in He received his medical degree from Howard University of Medicine, and a of degree from University, He completed his residency at New Medical Center, Department of and Memorial Sloan Kettering Cancer Center in New York, he served as In addition, he spent years as a National Institutes of research oncology at Cornell University School of Medicine cancer his he completed a fellowship at the Medical Center, Department of and has more than and and is of on and He has extensive to of throughout the United States and Roswell Park American Association Award it is research or developing new procedures and at Roswell Park Comprehensive Cancer Center. Department of Eric MD, was recognized for his approach for prostate cancer by the American Association a award for MD: Eric a he for is known as or This which has the for or the of the is often a treatment for prostate cancer. At Roswell of these are with a that a in patients. was one of selected by as award a “We Dr. on this from our around the said MD, Chair of the Department of and Director of Surgery at Roswell Park. information on and cancer for this to

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.